Wall Street Zen cut shares of Brainsway (NASDAQ:BWAY – Free Report) from a buy rating to a hold rating in a report released on Saturday.
BWAY has been the topic of a number of other reports. New Street Research reissued a “buy” rating on shares of Brainsway in a report on Friday. Zacks Research raised shares of Brainsway from a “hold” rating to a “strong-buy” rating in a research note on Monday, July 13th. Weiss Ratings reiterated a “buy (b-)” rating on shares of Brainsway in a report on Tuesday, July 21st. HC Wainwright reissued a “buy” rating and issued a $14.00 price objective on shares of Brainsway in a research note on Friday, July 17th. Finally, BTIG Research began coverage on Brainsway in a report on Monday, July 20th. They issued a “buy” rating and a $18.00 price objective for the company. One analyst has rated the stock with a Strong Buy rating and five have assigned a Buy rating to the company’s stock. Based on data from MarketBeat.com, Brainsway presently has a consensus rating of “Buy” and a consensus price target of $15.67.
Check Out Our Latest Research Report on BWAY
Brainsway Trading Down 1.3%
Brainsway (NASDAQ:BWAY – Get Free Report) last released its quarterly earnings results on Wednesday, May 13th. The company reported $0.12 earnings per share for the quarter, topping the consensus estimate of $0.05 by $0.07. Brainsway had a return on equity of 12.28% and a net margin of 15.68%.The company had revenue of $15.53 million for the quarter, compared to analysts’ expectations of $14.63 million. As a group, analysts predict that Brainsway will post 0.33 earnings per share for the current fiscal year.
Institutional Trading of Brainsway
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Masters Capital Management LLC raised its holdings in Brainsway by 65.0% during the 1st quarter. Masters Capital Management LLC now owns 1,650,000 shares of the company’s stock worth $21,928,000 after purchasing an additional 650,000 shares during the last quarter. Renaissance Technologies LLC boosted its stake in shares of Brainsway by 87.2% in the 1st quarter. Renaissance Technologies LLC now owns 518,420 shares of the company’s stock valued at $6,890,000 after purchasing an additional 241,560 shares during the last quarter. Y.D. More Investments Ltd boosted its stake in shares of Brainsway by 136.6% in the 1st quarter. Y.D. More Investments Ltd now owns 272,004 shares of the company’s stock valued at $3,615,000 after purchasing an additional 157,042 shares during the last quarter. Sei Investments Co. increased its position in shares of Brainsway by 262.5% during the first quarter. Sei Investments Co. now owns 226,378 shares of the company’s stock worth $3,009,000 after buying an additional 163,925 shares during the period. Finally, ARK Investment Management LLC acquired a new stake in shares of Brainsway during the fourth quarter worth $2,422,000. Institutional investors and hedge funds own 30.11% of the company’s stock.
About Brainsway
Brainsway Ltd is a medical device company specializing in non-invasive neuromodulation therapies. Publicly traded on the NASDAQ under the symbol BWAY, the company develops and commercializes deep transcranial magnetic stimulation (Deep TMS) systems designed to treat a range of neuropsychiatric and neurological disorders. Brainsway’s technology aims to offer an alternative or complement to traditional pharmacological therapies by targeting precise brain regions with its patented coil designs.
The company’s flagship Deep TMS platform utilizes proprietary H-coil arrays engineered to reach deeper cortical structures than conventional TMS devices.
Recommended Stories
- Five stocks we like better than Brainsway
- AirJoule’s Kubota Deal Is a Major Validation—But the Hard Part Comes Next
- Dividend Stocks May Be the Quiet Rotation Trade Investors Are Missing Now
- Refiner Stocks Are Near Record Highs—Can Iran-Driven Margins Keep Them There?
- Verizon May Be an AI Infrastructure Stock Hiding in Plain Sight
Receive News & Ratings for Brainsway Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brainsway and related companies with MarketBeat.com's FREE daily email newsletter.
